Do analysts rate MOR or DRUG?

Bright Minds Biosciences has a consensus target price of $143.83, suggesting a potential upside of 120.74%. Given Bright Minds Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Bright Minds Biosciences is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Bright Minds Biosciences 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00

Do analysts recommend RGC or DRUG?

Bright Minds Biosciences has a consensus target price of $143.83, suggesting a potential upside of 120.74%. Given Bright Minds Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Bright Minds Biosciences is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Bright Minds Biosciences 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00

Which has higher valuation and earnings, RGC or DRUG?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A Bright Minds Biosciences N/A N/A -$8.74M -$2.08 N/A

Is RGC or DRUG more profitable?

Regencell Bioscience's return on equity of 0.00% beat Bright Minds Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Regencell Bioscience N/A N/A N/A Bright Minds Biosciences N/A -12.46% -12.30%

Does the media favor RGC or DRUG?

In the previous week, Bright Minds Biosciences had 3 more articles in the media than Regencell Bioscience. MarketBeat recorded 4 mentions for Bright Minds Biosciences and 1 mentions for Regencell Bioscience. Bright Minds Biosciences' average media sentiment score of 0.94 beat Regencell Bioscience's score of 0.00 indicating that Bright Minds Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regencell Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bright Minds Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SUPN or DRUG?

In the previous week, Supernus Pharmaceuticals had 2 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 6 mentions for Supernus Pharmaceuticals and 4 mentions for Bright Minds Biosciences. Supernus Pharmaceuticals' average media sentiment score of 1.03 beat Bright Minds Biosciences' score of 0.94 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Supernus Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bright Minds Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, TRVI or DRUG?

Trevi Therapeutics is trading at a lower price-to-earnings ratio than Bright Minds Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Trevi Therapeutics N/A N/A -$42.76M -$0.34 N/A Bright Minds Biosciences N/A N/A -$8.74M -$2.08 N/A

Is TRVI or DRUG more profitable?

Bright Minds Biosciences' return on equity of -12.46% beat Trevi Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Trevi Therapeutics N/A -23.59% -22.64% Bright Minds Biosciences N/A -12.46% -12.30%

Does the media refer more to TRVI or DRUG?

In the previous week, Trevi Therapeutics had 1 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 5 mentions for Trevi Therapeutics and 4 mentions for Bright Minds Biosciences. Trevi Therapeutics' average media sentiment score of 1.27 beat Bright Minds Biosciences' score of 0.94 indicating that Trevi Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trevi Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bright Minds Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Bright Minds Biosciences (DRUG) Competitors

$65.16 -2.86 (-4.20%)

As of 04:00 PM Eastern

Compare

DRUG vs. MOR, ATAI, RGC, SUPN, and TRVI

Should you buy Bright Minds Biosciences stock or one of its competitors? Bright Minds Biosciences's main competitors and comparable companies include MorphoSys (MOR), Atai Beckley (ATAI), Regencell Bioscience (RGC), Supernus Pharmaceuticals (SUPN), and Trevi Therapeutics (TRVI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Bright Minds Biosciences compare to MorphoSys?

MorphoSys (NASDAQ:MOR) and Bright Minds Biosciences (NASDAQ:DRUG) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

18.4% of MorphoSys shares are owned by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by company insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Bright Minds Biosciences has lower revenue, but higher earnings than MorphoSys. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.08	N/A

Bright Minds Biosciences has a consensus target price of $143.83, suggesting a potential upside of 120.74%. Given Bright Minds Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Bright Minds Biosciences is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Bright Minds Biosciences	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00

In the previous week, Bright Minds Biosciences had 4 more articles in the media than MorphoSys. MarketBeat recorded 4 mentions for Bright Minds Biosciences and 0 mentions for MorphoSys. Bright Minds Biosciences' average media sentiment score of 0.94 beat MorphoSys' score of 0.00 indicating that Bright Minds Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
MorphoSys	Neutral
Bright Minds Biosciences	Positive

MorphoSys has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Comparatively, Bright Minds Biosciences has a beta of -5.36, suggesting that its share price is 636% less volatile than the broader market.

Bright Minds Biosciences has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Bright Minds Biosciences' return on equity of -12.46% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MorphoSys	-226.79%	-694.31%	-22.55%
Bright Minds Biosciences	N/A	-12.46%	-12.30%

Summary

Bright Minds Biosciences beats MorphoSys on 13 of the 16 factors compared between the two stocks.

How does Bright Minds Biosciences compare to Atai Beckley?

Atai Beckley (NASDAQ:ATAI) and Bright Minds Biosciences (NASDAQ:DRUG) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and dividends.

28.4% of Atai Beckley shares are owned by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are owned by institutional investors. 19.8% of Atai Beckley shares are owned by company insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Atai Beckley presently has a consensus price target of $10.56, suggesting a potential upside of 42.85%. Bright Minds Biosciences has a consensus price target of $143.83, suggesting a potential upside of 120.74%. Given Bright Minds Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Bright Minds Biosciences is more favorable than Atai Beckley.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atai Beckley	1 Sell rating(s)	14 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.06
Bright Minds Biosciences	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00

Atai Beckley has a beta of 1.54, meaning that its stock price is 54% more volatile than the broader market. Comparatively, Bright Minds Biosciences has a beta of -5.36, meaning that its stock price is 636% less volatile than the broader market.

In the previous week, Bright Minds Biosciences had 4 more articles in the media than Atai Beckley. MarketBeat recorded 4 mentions for Bright Minds Biosciences and 0 mentions for Atai Beckley. Bright Minds Biosciences' average media sentiment score of 0.94 beat Atai Beckley's score of 0.00 indicating that Bright Minds Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Atai Beckley	Neutral
Bright Minds Biosciences	Positive

Bright Minds Biosciences has lower revenue, but higher earnings than Atai Beckley. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atai Beckley	$4.09M	670.09	-$660.05M	-$2.18	N/A
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.08	N/A

Bright Minds Biosciences has a net margin of 0.00% compared to Atai Beckley's net margin of -14,938.36%. Bright Minds Biosciences' return on equity of -12.46% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atai Beckley	-14,938.36%	-88.30%	-58.88%
Bright Minds Biosciences	N/A	-12.46%	-12.30%

Summary

Bright Minds Biosciences beats Atai Beckley on 12 of the 15 factors compared between the two stocks.

How does Bright Minds Biosciences compare to Regencell Bioscience?

Regencell Bioscience (NASDAQ:RGC) and Bright Minds Biosciences (NASDAQ:DRUG) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

In the previous week, Bright Minds Biosciences had 3 more articles in the media than Regencell Bioscience. MarketBeat recorded 4 mentions for Bright Minds Biosciences and 1 mentions for Regencell Bioscience. Bright Minds Biosciences' average media sentiment score of 0.94 beat Regencell Bioscience's score of 0.00 indicating that Bright Minds Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regencell Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bright Minds Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

0.1% of Regencell Bioscience shares are owned by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are owned by institutional investors. 2.0% of Regencell Bioscience shares are owned by insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Regencell Bioscience's return on equity of 0.00% beat Bright Minds Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Bright Minds Biosciences	N/A	-12.46%	-12.30%

Regencell Bioscience has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market. Comparatively, Bright Minds Biosciences has a beta of -5.36, meaning that its stock price is 636% less volatile than the broader market.

Bright Minds Biosciences has a consensus target price of $143.83, suggesting a potential upside of 120.74%. Given Bright Minds Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Bright Minds Biosciences is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bright Minds Biosciences	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.08	N/A

Summary

Bright Minds Biosciences beats Regencell Bioscience on 8 of the 12 factors compared between the two stocks.

How does Bright Minds Biosciences compare to Supernus Pharmaceuticals?

Supernus Pharmaceuticals (NASDAQ:SUPN) and Bright Minds Biosciences (NASDAQ:DRUG) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

Supernus Pharmaceuticals has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market. Comparatively, Bright Minds Biosciences has a beta of -5.36, suggesting that its stock price is 636% less volatile than the broader market.

Bright Minds Biosciences has a net margin of 0.00% compared to Supernus Pharmaceuticals' net margin of -13.23%. Supernus Pharmaceuticals' return on equity of 11.13% beat Bright Minds Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Supernus Pharmaceuticals	-13.23%	11.13%	8.10%
Bright Minds Biosciences	N/A	-12.46%	-12.30%

Bright Minds Biosciences has lower revenue, but higher earnings than Supernus Pharmaceuticals. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Supernus Pharmaceuticals	$830.44M	3.05	-$38.55M	-$1.92	N/A
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.08	N/A

Supernus Pharmaceuticals currently has a consensus target price of $62.83, indicating a potential upside of 44.34%. Bright Minds Biosciences has a consensus target price of $143.83, indicating a potential upside of 120.74%. Given Bright Minds Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Bright Minds Biosciences is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Supernus Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Bright Minds Biosciences	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00

40.5% of Bright Minds Biosciences shares are owned by institutional investors. 8.5% of Supernus Pharmaceuticals shares are owned by company insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Supernus Pharmaceuticals had 2 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 6 mentions for Supernus Pharmaceuticals and 4 mentions for Bright Minds Biosciences. Supernus Pharmaceuticals' average media sentiment score of 1.03 beat Bright Minds Biosciences' score of 0.94 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Supernus Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bright Minds Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Supernus Pharmaceuticals beats Bright Minds Biosciences on 8 of the 15 factors compared between the two stocks.

How does Bright Minds Biosciences compare to Trevi Therapeutics?

Trevi Therapeutics (NASDAQ:TRVI) and Bright Minds Biosciences (NASDAQ:DRUG) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment.

95.8% of Trevi Therapeutics shares are held by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are held by institutional investors. 15.4% of Trevi Therapeutics shares are held by company insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Trevi Therapeutics presently has a consensus price target of $27.08, suggesting a potential upside of 56.91%. Bright Minds Biosciences has a consensus price target of $143.83, suggesting a potential upside of 120.74%. Given Bright Minds Biosciences' higher probable upside, analysts clearly believe Bright Minds Biosciences is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Bright Minds Biosciences	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00

Trevi Therapeutics is trading at a lower price-to-earnings ratio than Bright Minds Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.34	N/A
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.08	N/A

In the previous week, Trevi Therapeutics had 1 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 5 mentions for Trevi Therapeutics and 4 mentions for Bright Minds Biosciences. Trevi Therapeutics' average media sentiment score of 1.27 beat Bright Minds Biosciences' score of 0.94 indicating that Trevi Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trevi Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bright Minds Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bright Minds Biosciences' return on equity of -12.46% beat Trevi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-23.59%	-22.64%
Bright Minds Biosciences	N/A	-12.46%	-12.30%

Trevi Therapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the broader market. Comparatively, Bright Minds Biosciences has a beta of -5.36, indicating that its stock price is 636% less volatile than the broader market.

Summary

Trevi Therapeutics beats Bright Minds Biosciences on 7 of the 13 factors compared between the two stocks.

Get Bright Minds Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DRUG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DRUG vs. The Competition

Export

Metric	Bright Minds Biosciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$634.01M	$12.17B	$7.17B	$12.88B
Dividend Yield	N/A	2.59%	2.53%	8.57%
P/E Ratio	-31.33	787.21	272.99	25.40
Price / Sales	N/A	759.16	612.73	97.75
Price / Cash	N/A	94.80	77.82	52.27
Price / Book	2.85	12.46	12.85	6.17
Net Income	-$8.74M	$2.82B	$3.47B	$349.50M
7 Day Performance	-10.51%	3.80%	1.24%	-0.05%
1 Month Performance	-15.76%	6.77%	5.81%	0.80%
1 Year Performance	48.26%	10.44%	25.75%	15.62%

Bright Minds Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DRUG Bright Minds Biosciences	2.7423 of 5 stars	$65.16 -4.2%	$143.83 +120.7%	+57.2%	$634.01M	N/A	N/A	N/A	News Coverage
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730
ATAI Atai Beckley	2.8377 of 5 stars	$7.44 +0.8%	$10.56 +41.9%	+62.4%	$2.76B	$4.47M	N/A	80
RGC Regencell Bioscience	0.0594 of 5 stars	$5.54 +4.7%	N/A	-53.1%	$2.74B	N/A	N/A	10
SUPN Supernus Pharmaceuticals	4.5157 of 5 stars	$45.36 +0.6%	$62.83 +38.5%	-2.1%	$2.64B	$718.95M	N/A	580	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DRUG) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bright Minds Biosciences (DRUG) Competitors

DRUG vs. MOR, ATAI, RGC, SUPN, and TRVI

How does Bright Minds Biosciences compare to MorphoSys?

Summary

How does Bright Minds Biosciences compare to Atai Beckley?

Summary

How does Bright Minds Biosciences compare to Regencell Bioscience?

Summary

How does Bright Minds Biosciences compare to Supernus Pharmaceuticals?

Summary

How does Bright Minds Biosciences compare to Trevi Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DRUG vs. The Competition

Bright Minds Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bright Minds Biosciences (DRUG) Competitors

DRUG vs. MOR, ATAI, RGC, SUPN, and TRVI

How does Bright Minds Biosciences compare to MorphoSys?

Do insiders and institutionals hold more shares of MOR or DRUG?

Which has stronger valuation & earnings, MOR or DRUG?

Do analysts rate MOR or DRUG?

Does the media favor MOR or DRUG?

Which has more volatility & risk, MOR or DRUG?

Is MOR or DRUG more profitable?

Summary

How does Bright Minds Biosciences compare to Atai Beckley?

Do institutionals & insiders hold more shares of ATAI or DRUG?

Do analysts rate ATAI or DRUG?

Which has more risk and volatility, ATAI or DRUG?

Does the media favor ATAI or DRUG?

Which has better earnings and valuation, ATAI or DRUG?

Is ATAI or DRUG more profitable?

Summary

How does Bright Minds Biosciences compare to Regencell Bioscience?

Does the media favor RGC or DRUG?

Do institutionals and insiders hold more shares of RGC or DRUG?

Is RGC or DRUG more profitable?

Which has more risk & volatility, RGC or DRUG?

Do analysts recommend RGC or DRUG?

Which has higher valuation and earnings, RGC or DRUG?

Summary

How does Bright Minds Biosciences compare to Supernus Pharmaceuticals?

Which has more risk and volatility, SUPN or DRUG?

Is SUPN or DRUG more profitable?

Which has higher earnings and valuation, SUPN or DRUG?

Do analysts recommend SUPN or DRUG?

Do insiders & institutionals believe in SUPN or DRUG?

Does the media prefer SUPN or DRUG?

Summary

How does Bright Minds Biosciences compare to Trevi Therapeutics?

Do insiders and institutionals hold more shares of TRVI or DRUG?

Do analysts prefer TRVI or DRUG?

Which has better earnings and valuation, TRVI or DRUG?

Does the media refer more to TRVI or DRUG?

Is TRVI or DRUG more profitable?

Which has more risk & volatility, TRVI or DRUG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DRUG vs. The Competition

Bright Minds Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools